Synthesis, Characterization, and In Vitro Anticancer Evaluation of Novel 2,5-Disubstituted 1,3,4-Oxadiazole Analogue

Table 2

Five dose vitro testing results of compound.

Panel/cell line	18 (776965)			27 (776971)
	GI50	TGI	LC50	GI50	TGI	LC50
Leukemia
CCRF-CEM	1.70	7.79	>100	0.414	3.74	>100
HL-60(TB)	3.43	21.2	>100	2.85	7.88	>100
K-562	3.29	14.4	>100	2.59	>100	>100
MOLT-4	2.69	9.22	>100	2.18	7.89	>100
RPMI-8226	1.94	6.67	>100	2.39	8.45	>100
SR	2.03	10.9	>100	7.34	8.54	>100
Non-small cell lung Cancer
A549/ATCC	15.7	>100	>100	8.49	24.2	62.3
HOP-62	12.6	34.3	93.5	2.98	13.0	52.2
HOP-92	3.34	15.3	53.3	1.27	5.37	29.2
NCI-H226	11.5	94.4	>100	5.99	31.4	>100
NCI-H23	11.3	39.5	>100	4.66	20.7	83.1
NCI-H322M	15.8	34.4	75.1	14.9	34.4	79.6
NCI-H460	6.63	28.3	>100	10.4	24.4	57.1
NCI-H522	2.27	5.90	26.7	6.34	21.1	55.6
Colon cancer
COLO 205	3.55	13.2	44.9	1.89	4.44	12.3
HCC-2998	12.7	27.5	59.7	4.40	15.3	50.9
HCT-116	1.41	3.10	6.83	0.431	1.64	5.82
HCT-15	3.30	13.5	44.9	2.13	7.69	44.0
HT29	3.78	12.9	83.3	2.02	4.43	9.70
KM12	10.4	28.4	77.9	2.85	11.8	96.5
SW-620	1.87	4.16	9.25	1.08	4.79	32.4
CNS cancer
SF-268	10.7	42.0	>100	3.41	15.9	69.8
SF-295	11.2	32.2	92.7	3.48	14.1	42.1
SNB-19	12.9	38.1	>100	3.78	17.0	63.4
SNB-75	6.07	21.4	53.5	2.16	9.74	45.8
U251	4.12	14.9	43.3	1.58	3.62	8.29
Melanoma
LOX IMVI	1.74	4.30	13.1	1.59	4.32	17.1
MALME-3M	3.94	16.2	89.6	3.65	15.6	>100
M14	3.16	15.2	54.7	2.33	7.40	34.5
MDA-MB-435	3.51	17.5	77.8	3.06	11.9	40.5
SK-MEL-5	3.43	16.4	55.2	1.90	3.97	8.30
UACC-257	4.79	24.4	88.2	3.28	14.9	59.4
UACC-62	3.43	15.6	47.7	5.62	20.7	53.4
Ovarian cancer
IGROV1	5.20	27.1	>100	3.25	22.0	>100
OVCAR-3	3.25	11.0	35.4	2.41	6.65	35.1
OVCAR-4	4.23	18.3	47.2	2.36	10.2	>100
OVCAR-8	2.71	NT	>100	2.12	7.52	>100
NCI/ADR-RES	14.4	71.1	>100	2.84	10.9	>100
SK-OV-3	18.3	38.1	79.3	11.8	32.7	90.3
Renal cancer
786-0	4.01	14.6	58.2	3.09	11.8	51.4
A498	13.3	27.1	55.1	0.409	18.7	44.9
CAKI-1	3.65	14.4	48.2	2.29	14.9	>100
RXF 393	2.93	10.9	79.1	2.71	10.6	45.0
SN12C	3.46	28.2	>100	2.76	11.9	>100
TK-10	5.23	16.0	54.1	3.91	9.92	96.5
UO-31	1.72	3.72	8.05	1.19	10.2	48.4
Prostate cancer
PC-3	4.16	70.6	>100	2.71	15.4	>100
DU-145	5.18	18.5	48.9	5.46	45.7	>100
Breast cancer
MCF7	2.41	12.9	58.5	0.949	5.38	55.6
MDA-MB-231/ATCC	3.29	14.7	>100	1.64	4.62	70.7
HS 578T	13.3	>100	>100	4.39	33.8	>100
BT-549	2.56	10.2	34.2	1.77	4.06	9.31
T-47D	3.04	17.1	>100	2.61	14.6	>100
MDA-MB-468	2.29	9.87	59.2	3.95	18.3	74.4